NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all Ame ...

KITCHENER, ON, June 20, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that it held its Annual Meeting of Shareholders on June 20, 2025. Each of the proposals submitted for shareholder approval was approved. Specifically, the shareholders approved: The election of Shawn (Xiaohua) Qu, Yan Zhuang, Harry E. Ruda, Andrew (Luen Cheung) Wong, Lauren C. Templeton, Leslie Li Hsien Chang, and Yuan Yuan Zhang Qu each as a director of the Company until the n ...

Iqos logo is seen at the store in Warsaw, Poland on November 13, 2024. (Photo by Jakub ... More Porzycki/NurPhoto via Getty Images)NurPhoto via Getty ImagesQuestion: Why would you pay 37 times earnings for Philip Morris stock when you can buy Google stock for a much cheaper valuation of 19 times earnings? You wouldn’t, especially when you consider three simple facts: Growth: Google’s revenue growth rate is accelerating at over 13% - better than Philip Morris’s revenue growth of 7%. Over the last three years ...

Core Insights - Ellomay Capital Ltd. has successfully closed an investment transaction with Clal Insurance Company Ltd. for a 198 MW solar portfolio in Italy, granting Clal a 49% interest in the portfolio [1][3] Company Overview - Ellomay Capital Ltd. is an Israeli company listed on the NYSE American and the Tel Aviv Stock Exchange, focusing on renewable energy and power sectors in Europe, the USA, and Israel since 2009 [4] Investment Details - The investment transaction with Clal involves both operating projects and projects under construction and development in Italy [1] - Clal received a warrant to purchase ordinary shares of the Company as part of the transaction [2] Strategic Significance - The CEO of Ellomay highlighted the transaction as a significant milestone in the company's strategic growth and development plan, indicating strong confidence in the company's vision and leadership [3]

Whatever one feels about Tesla's controversial CEO, Elon Musk, one thing is clear: the EV company and its leader know how to sell a robotaxi vision. As a testament: Tesla doesn't have a single robotaxi on the road providing paid rides, years after Musk has promised multiple times that it's just around the corner. The closest glimpse of an unmanned Tesla on public roads only came on June 10 with a short clip on X that showed a black Model Y appearing to drive itself on Austin's road with another Tesla trail ...

Core Viewpoint - AES Corporation's stock has dropped nearly 8% following proposed changes to tax incentives for renewable energy, which could significantly impact the company's operations as it derives a substantial portion of its power capacity from renewable sources [2] Group 1: Financial Performance - AES's revenues have declined, with an average growth rate of 2.5% over the last three years compared to 5.5% for the S&P 500 [4] - The company's revenues decreased by 3.2% from $13 billion to $12 billion in the past 12 months, while the S&P 500 experienced a growth of 5.5% [4] - Quarterly revenues fell by 5.2% to $2.9 billion from $3.1 billion year-over-year, contrasting with a 4.8% improvement for the S&P 500 [4] Group 2: Valuation Metrics - AES has a price-to-sales (P/S) ratio of 0.7, significantly lower than the S&P 500's ratio of 3.1 [5] - The price-to-earnings (P/E) ratio for AES is 6.3, compared to the S&P 500's 26.9, indicating that AES stock appears inexpensive relative to the broader market [5][3] Group 3: Profitability - AES's operating income for the last four quarters was $1.8 billion, resulting in an operating margin of 15.2% [6] - The operating cash flow (OCF) during this period was $3.0 billion, yielding an OCF margin of 24.8%, which is higher than the S&P 500's 14.9% [6] - AES's net income reached $1.3 billion, reflecting a net income margin of 10.7%, slightly below the S&P 500's 11.6% [6] Group 4: Financial Stability - AES's debt stood at $31 billion, with a market capitalization of $7.5 billion, resulting in a debt-to-equity ratio of 375.6%, significantly higher than the S&P 500's 19.4% [7] - Cash and cash equivalents amount to $1.8 billion out of total assets of $49 billion, leading to a low cash-to-assets ratio of 3.7% [7] Group 5: Downturn Resilience - AES stock has underperformed against the S&P 500 during recent downturns, including a 57.5% drop during the inflation shock and a 54.5% decline during the COVID pandemic [9][10] - The stock has not yet returned to its pre-crisis highs, indicating weak resilience during market downturns [9][10] Group 6: Overall Assessment - AES's performance across key parameters is summarized as follows: weak growth, neutral profitability, extremely weak financial stability, and extremely weak downturn resilience, leading to an overall assessment of very weak [12]

Oil giants Chevron (CVX -0.46%) and ExxonMobil (XOM -0.71%) can read the writing on the wall: They can see that fossil fuels will eventually go extinct. That's leading these energy giants to invest in expanding into lower-carbon energy. One area both oil stocks are expanding into is lithium, a key ingredient for making batteries for electric vehicles (EVs). Exxon entered the sector in 2023 by acquiring land in Arkansas' Smackover Formation, which is rich in lithium brine. Chevron is now following in Exxon's ...

Core Insights - SoFi Technologies, Inc. has experienced a stock price increase of over 15% in the past month, influenced by the successful IPO of Chime, which has positively impacted the fintech sector [2] - Despite the recent rise, SoFi's stock, trading around $15, is considered unattractive due to concerns over its high valuation relative to its performance [2][10] Financial Performance - SoFi Technologies has a price-to-sales (P/S) ratio of 5.9, significantly higher than the S&P 500's 3.1, and a price-to-earnings (P/E) ratio of 32.9 compared to the benchmark's 26.9 [6] - The company has achieved an average revenue growth rate of 36.2% over the last three years, with a recent revenue increase of 25.9% from $2.2 billion to $2.8 billion in the last 12 months [6] - Quarterly revenues grew by 31.7% to $772 million from $586 million year-over-year [6] Profitability and Financial Stability - SoFi's profit margins are reported to be weaker than most companies in the Trefis coverage universe [7] - The company's balance sheet is described as strong, with a cash-to-assets ratio of 11.2% and a moderate debt-to-equity ratio of 19.8% [8][13] Downturn Resilience - SoFi stock has shown poor resilience during market downturns, performing worse than the S&P 500 in recent declines [9][14] - The stock has not yet recovered to its pre-crisis high, with a significant drop of 83.3% from its peak of $25.78 in February 2021 to $4.30 in December 2022 [14] Overall Assessment - The overall performance of SoFi Technologies across analyzed parameters is deemed neutral, with high valuation concerns compared to historical averages [10] - The company’s current valuation appears excessive given its moderate operating performance and financial condition [3][11]

Core Viewpoint - Madrigal Pharmaceuticals has received a positive opinion from the CHMP of the EMA recommending approval of resmetirom (Rezdiffra) for treating adults with noncirrhotic MASH with moderate to advanced liver fibrosis, with a decision from the European Commission expected in August 2025 [1][2][7] Company Overview - Madrigal Pharmaceuticals is focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need [16] - Resmetirom is the first approved medication for MASH in the U.S. and is designed as a once-daily, oral, liver-directed THR-β agonist [7][16] Product Details - Resmetirom has shown positive results in the pivotal Phase 3 MAESTRO-NASH trial, achieving both fibrosis improvement and MASH resolution primary endpoints [2][8] - In the U.S., resmetirom is indicated for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in conjunction with diet and exercise [8][10] Industry Context - MASH is a leading cause of liver-related mortality and is the fastest-growing indication for liver transplantation in Europe [4][5] - The prevalence of MASH is expected to increase as awareness improves, leading to a growing number of diagnosed patients with moderate to advanced fibrosis or compensated MASH cirrhosis [6]

Core Viewpoint - FLSmidth & Co. A/S has announced a share buy-back programme of up to DKK 1.4 billion, marking its first such initiative since 2012, to be completed before the next Annual General Meeting scheduled for 24 March 2026 [1] Financial Performance - The decision to initiate the share buy-back programme is supported by a significantly stronger and more stable financial performance, with a strategic shift towards higher-margin technology and service offerings, reducing exposure to volatile projects [2] - The company has undergone material de-risking of its order backlog through strategic portfolio optimisation [2] Shareholder Value - The Board of Directors aims to balance investments in growth with returning value to shareholders, leveraging substantial headroom to the targeted leverage ratio [3] - The share buy-back programme is intended to adjust the capital structure and meet obligations from share-based incentive programmes, with any repurchased shares not used for these obligations proposed for cancellation [4] Programme Details - The share buy-back programme is authorized to acquire up to 10 percent of the company's share capital, with a maximum of 4,600,000 shares, representing approximately 8 percent of the share capital [5][7] - The programme will commence on 25 June 2025 and conclude no later than 20 March 2026 [7] - Shares will be repurchased at prices not exceeding the higher of the last independent transaction price or the highest independent bid, with a deviation limit of 10% from the official price on Nasdaq Copenhagen [9] Execution and Management - The programme will be executed in compliance with EU regulations on market abuse, with BNP Paribas appointed to manage the buy-back independently [6] - FLSmidth retains the right to suspend the programme at any time, with announcements to be made regarding transactions every seven trading days [10]